The Swiss life-sciences company said it expected accelerated sales growth in the fourth quarter on the back of the timing of ...

Diabetic retinopathy appears to be more common in young people than earlier thought, leaving more of them at risk for eye ...

There is a lack of understanding among neurologists on how to balance the risks for and benefits of corticosteroids in ...

CHICAGO -- An artificial intelligence (AI)-based study of home monitoring for neovascular age-related macular degeneration ...

Sandoz, Eli Lilly, Bayer, and Genentech executives tell what strikes them about the 2024 presidential race — and how the ...

Roche’s chronic cough program has sputtered to a halt. The drugmaker, which axed the program after the drug candidate ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive topline one-year results from ...

Roche has returned the rights to UCB’s anti-tau antibody bepranemab, walking away from a $120 million bet on the Alzheimer’s ...

Regulators are supposed to abide by society's “bargain” with them: Civil servants are granted lifetime tenure and protected ...

Genentech, the biotech unit of Swiss major Roche, has been marketing lung cancer drugs for nearly two decades, starting with ...

Some of the soundbite health care policy proposals that candidates bring up for short-term political impact could in practice ...

Itovebi — also known as inavolisib — is designed to be given with drugs from Pfizer Inc. and AstraZeneca plc to treat adults ...